Valuation: Arcus Biosciences, Inc.

Market Cap 363.74Cr 319.36Cr 293.96Cr 273.92Cr 516.59Cr 35TCr 527.09Cr 3.54TCr 1.37TCr 17TCr 1.37TCr 1.34TCr 59TCr P/E 2026 *
-7.87x
P/E 2027 * -8.58x
Enterprise Value 301.6Cr 264.81Cr 243.74Cr 227.13Cr 428.35Cr 29TCr 437.05Cr 2.93TCr 1.14TCr 14TCr 1.13TCr 1.11TCr 49TCr EV / Sales 2026 *
35.5x
EV / Sales 2027 * 36.3x
Free-Float
70.85%
Yield 2026 *
-
Yield 2027 * -
1 day-6.20%
1 week+0.42%
Current month-6.20%
1 month+12.66%
3 months+32.42%
6 months+21.36%
Current year+21.36%
1 week 28.78
Extreme 28.775
31.74
1 month 21.84
Extreme 21.84
31.74
Current year 18.52
Extreme 18.515
31.74
1 year 8.03
Extreme 8.03
31.74
3 years 6.5
Extreme 6.5
31.74
5 years 6.5
Extreme 6.5
49.1
10 years 6.3
Extreme 6.3
49.1
Manager TitleAgeSince
President 68 01/05/2015
Chief Executive Officer 67 01/05/2015
Director of Finance/CFO 53 01/08/2020
Director TitleAgeSince
Chairman 67 01/12/2017
Director/Board Member 65 18/09/2017
Director/Board Member 71 01/05/2015
Date Insider Type Main position Quantity % Market Cap.
24/06Sell

Founder

-6,431 0.0051%
11/06Free

Director

22,600 0.0180%
11/06Fiscal year

General Counsel

68,180 0.0542%
Change 5-day change 1-year change 3-year change Capi.($)
-6.20%+0.42%+245.93%+42.39% 363.74Cr
-0.30%+4.65%+0.61%+6.20% 4.86TCr
+0.12%+10.45%+408.29%+600.97% 3.99TCr
+5.17%+9.47%+24.96%-9.60% 3.39TCr
+2.02%+4.91%+18.59%+63.06% 3.23TCr
+0.69%+1.04%+14.23%+30.86% 2.47TCr
+0.40%+12.51% - - 1.66TCr
+2.64%+6.00%+69.30%+126.33% 1.55TCr
+0.44%+0.70%+13.35%+18.06% 1.36TCr
+0.77%+10.67%+17.58%-30.04% 1.34TCr
Average +0.57%+6.39%+90.32%+94.25% 2.42TCr
Weighted average by Cap. +1.18%+7.04%+90.82%+127.16%

Financials

2026 *2027 *
Net sales 8.51Cr 7.47Cr 6.87Cr 6.41Cr 12Cr 808.7Cr 12Cr 83Cr 32Cr 396.95Cr 32Cr 31Cr 1.38TCr 9.31Cr 8.17Cr 7.52Cr 7.01Cr 13Cr 884.72Cr 13Cr 90Cr 35Cr 434.27Cr 35Cr 34Cr 1.51TCr
Net income -46Cr -40Cr -37Cr -34Cr -65Cr -4.34TCr -66Cr -443.61Cr -171.88Cr -2.13TCr -171.36Cr -167.65Cr -7.41TCr -43Cr -38Cr -35Cr -32Cr -61Cr -4.09TCr -62Cr -418.48Cr -162.14Cr -2.01TCr -161.65Cr -158.15Cr -6.99TCr
Net Debt -62Cr -55Cr -50Cr -47Cr -88Cr -5.91TCr -90Cr -603.95Cr -234Cr -2.9TCr -233.29Cr -228.25Cr -10TCr -26Cr -23Cr -21Cr -20Cr -37Cr -2.47TCr -38Cr -252.09Cr -98Cr -1.21TCr -97Cr -95Cr -4.21TCr
Logo Arcus Biosciences, Inc.
Arcus Biosciences, Inc. is a clinical-stage biopharmaceutical company developing differentiated molecules and combination therapies for people with cancer. The Company has a portfolio of investigational products, which are in clinical development with its advanced molecule, an anti-TIGIT antibody targeting lung and gastrointestinal cancers. The Company has approximately seven clinical programs that are focused on targets, including TIGIT, PD-1, adenosine A2a and A2b receptors, CD73, CD39, HIF-2a, and AXL. The Company is engaged in co-developing four investigational products, including zimberelimab (Arcuss anti-PD-1 molecule), domvanalimab (Arcuss anti-TIGIT antibody), etrumadenant (Arcuss adenosine receptor antagonist) and quemliclustat (Arcuss CD73 inhibitor). It is engaged in pursuing a Phase II and Phase III development program for domvanalimab in combination with its anti-PD-1 antibody, zimberelimab, in multiple settings, including lung and gastrointestinal cancer.
Employees
601
Date Price Change Volume
01/26/01 $28.92 -6.20% 16,64,831
30/26/30 $30.83 -0.80% 13,44,884
29/26/29 $31.08 +0.26% 15,65,332
26/26/26 $31.00 +2.48% 43,52,591
25/26/25 $30.25 +5.03% 25,09,348
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
28.92USD
Average target price
35.75USD
Spread / Average Target
+23.62%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. RCUS Stock